Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
11 hedge funds and large institutions have $96.9M invested in Calliditas Therapeutics AB American Depositary Shares in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 7 closing their positions.
42% more capital invested
Capital invested by funds: $68.1M → $96.9M (+$28.7M)
31% less funds holding
Funds holding: 16 → 11 (-5)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
86% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$21.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$8.19M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$7.61M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.72M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$2.67M |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$586K |
CALT Hedge Fund Activity: Q4 2020 in Review
11 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q4 2020, worth a combined $96.9M — up 42% from $68.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CALT and 2 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 1 added.
The largest buyer was HHLR Advisors, adding an estimated $21.2M. The largest seller was Vivo Capital, cutting an estimated $8.19M.
- 11 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q4 2020, down from 16 in Q3 2020.
- Funds reported $96.9M of Calliditas Therapeutics AB American Depositary Shares stock for Q4 2020, up 42% quarter-over-quarter.
- 2 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q4 2020 and 7 closed out, a net change of -5 holders.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q4 2020 was HHLR Advisors, an estimated $21.2M added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q4 2020 was Vivo Capital, an estimated $8.19M sold.
Based on aggregated 13F filings for Q4 2020.